<DOC>
	<DOCNO>NCT02447978</DOCNO>
	<brief_summary>The purpose study assess duration protection GSK DTaP vaccine prevent pertussis .</brief_summary>
	<brief_title>Duration Protection : GSK DTaP Vaccines</brief_title>
	<detailed_description />
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Kaiser Permanente Northern California ( KPNC ) member receive 5 dos acellular pertussis vaccine age 1 month 84 month KPNC . The 5th dose give age 47 84 month . All 5 DTaP dos receive manufactured GSK , depend study objective ( otherwise criterion apply ) . Born 1999 later . Inclusion criteria case : • All individual meet inclusion criterion test PCRpositive pertussis negative parapertussis study period . Inclusion criterion PCRnegative control : • All individual meet inclusion criterion test PCRnegative pertussis parapertussis study period . Inclusion criterion KPNCmatched control : All individual general KPNC population meeting inclusion criterion match PCRpositive case sex , age , race ethnic group , medical center . KPNC member day match case underwent PCR test ( anchor date ) . Individuals whose PCR test date ( anchor date ) less 2 week receive 5th DTaP dose . Individuals KPNC member great 3 month 5th DTaP dose PCR test date ( anchor date ) . Individuals receive reduced antigen content pertussis vaccine ( Tdap ) pertussiscontaining vaccine 5th DTaP dose PCR test date ( anchor date ) . Exclusion criterion control : • Individuals exclude serve control test positive pertussis .</criteria>
	<gender>All</gender>
	<minimum_age>47 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>